Renaissance Technologies
NGNE icon

Renaissance Technologies’s Neurogene NGNE Stock Holding History

Renaissance Technologies’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$875K Buy
43,400
+29,400
+210% +$569K ﹤0.01% 2336
2025
Q4 		$288K Buy
+14,000
New +$348K ﹤0.01% 2777
2024
Q4 		– Sell
-22,807
Closed -$957K – 3791
2024
Q3 		$957K Sell
22,807
-30,000
-57% -$1.16M ﹤0.01% 2471
2024
Q2 		$1.92M Sell
52,807
-5,900
-10% -$208K ﹤0.01% 1911
2024
Q1 		$2.99M Buy
58,707
+8,513
+17% +$284K ﹤0.01% 1771
2023
Q4 		$973K Buy
50,194
+9,332
+23% +$134K ﹤0.01% 2424
2023
Q3 		$646K Sell
40,862
-5,999
-13% -$88.6K ﹤0.01% 2594
2023
Q2 		$778K Buy
46,861
+1,130
+2% +$18.5K ﹤0.01% 2623
2023
Q1 		$640K Sell
45,731
-13,941
-23% -$163K ﹤0.01% 2747
2022
Q4 		$607K Sell
59,672
-12,431
-17% -$128K ﹤0.01% 2839
2022
Q3 		$923K Sell
72,103
-8,610
-11% -$176K ﹤0.01% 2548
2022
Q2 		$1.66M Buy
80,713
+17,265
+27% +$421K ﹤0.01% 2324
2022
Q1 		$2.39M Buy
63,448
+21,267
+50% +$1.24M ﹤0.01% 2104
2021
Q4 		$4.07M Buy
42,181
+4,336
+11% +$528K 0.01% 1655
2021
Q3 		$5.47M Buy
37,845
+9,045
+31% +$1.38M 0.01% 1411
2021
Q2 		$5.32M Sell
28,800
-2,097
-7% -$464K 0.01% 1598
2021
Q1 		$7.61M Sell
30,897
-7,238
-19% -$1.85M 0.01% 1371
2020
Q4 		$10.8M Sell
38,135
-3,722
-9% -$909K 0.01% 1113
2020
Q3 		$10M Sell
41,857
-10,158
-20% -$2.46M 0.01% 1134
2020
Q2 		$17.3M Buy
52,015
+9,660
+23% +$2.52M 0.01% 906
2020
Q1 		$9.64M Buy
42,355
+6,386
+18% +$1.31M 0.01% 1189
2019
Q4 		$8.86M Sell
35,969
-2,423
-6% -$241K 0.01% 1522
2019
Q3 		$2.19M Buy
38,392
+14,248
+59% +$869K ﹤0.01% 2234
2019
Q2 		$1.14M Buy
24,144
+5,035
+26% +$259K ﹤0.01% 2621
2019
Q1 		$1.03M Buy
19,109
+8,180
+75% +$413K ﹤0.01% 2656
2018
Q4 		$472K Buy
10,929
+3,547
+48% +$173K ﹤0.01% 2885
2018
Q3 		$433K Buy
7,382
+4,538
+160% +$268K ﹤0.01% 2898
2018
Q2 		$151K Buy
+2,844
New +$741K ﹤0.01% 3106
2018
Q1 		– Sell
-1,508
Closed -$355K – 3503
2017
Q4 		$355K Buy
+1,508
New +$353K ﹤0.01% 2973

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Renaissance Technologies's NGNE Position: Q1 2026 in Review

Renaissance Technologies increased its Neurogene (NGNE) stake by 210% in Q1 2026, buying an estimated $569K and bringing the position to 43,400 shares worth $875K. The position accounts for ﹤0.01% of the portfolio, ranked #2336.

Renaissance Technologies first reported a position in NGNE in Q4 2017 and has held it in 29 quarters since. The position peaked at $17.3M in Q2 2020. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Renaissance Technologies held 43,400 shares of Neurogene worth $875K as of Q1 2026.
  • Renaissance Technologies bought 29,400 Neurogene shares in Q1 2026, an estimated $569K.
  • Neurogene made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2336 holding.
  • Renaissance Technologies first reported a position in Neurogene in Q4 2017 and has held it in 29 quarters since.
  • Renaissance Technologies's Neurogene position peaked at $17.3M in Q2 2020.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.